Publication:
Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis

Simple item page
dc.contributor.authorAKYÜZ, GÜLSEREN DERYA
dc.contributor.authorsAki, S; Eskiyurt, N; Akarirmak, U; Tuzun, F; Eryavuz, M; Alper, S; Arpacioglu, O; Atalay, F; Kavuncu, V; Kokino, S; Kuru, O; Nas, K; Ozerbil, O; Savas, G; Sendur, OF; Soy, D; Akyuz, G
dc.date.accessioned2022-03-14T08:16:19Z
dc.date.available2022-03-14T08:16:19Z
dc.date.issued2003
dc.description.abstractThe aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules. This study was a multicentered retrospective, clinical, non-placebo controlled, study of 759 female subjects carried out at 26 centres in 6 different regions of Turkey. The mean age of our patients was 62.6 +/- 8.6, with 51.2% in the age range 60 to 69 years. 158 patients (20.8%) were considered to have upper GI tract complaints with nausea as the most often encountered symptom. Of the subjects with upper GI tract complaints, 20% reported discontinued drug use, and 30% reported the requirement of an additional drug in order to abolish their complaints. Approximately 537 (71%) of the patients stated they had been given written information about the administration of the drug, and at least 93 patients (12%) and 73 patients (18.4%) acknowledged non compliance with the safety and absorption rules, respectively. In our study, no significant difference was found between the adherence to the safety measures and upper GI tract complaints (p>0.05), but that upper GI tract complaints were higher in patients taking additional medication to alendronate (p<0.05).
dc.identifier.doi10.3349/ymj.2003.44.6.961
dc.identifier.eissn1976-2437
dc.identifier.issn0513-5796
dc.identifier.pubmed14703602
dc.identifier.urihttps://hdl.handle.net/11424/241370
dc.identifier.wosWOS:000187959500003
dc.language.isoeng
dc.publisherYONSEI UNIV COLL MEDICINE
dc.relation.ispartofYONSEI MEDICAL JOURNAL
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectosteoporosis
dc.subjectalendronate
dc.subjectgastrointestinal system
dc.subjectside effect profile
dc.subjectFRACTURE-INTERVENTION-TRIAL
dc.subjectBONE MASS
dc.subjectPOSTMENOPAUSAL WOMEN
dc.subjectVERTEBRAL FRACTURES
dc.subjectRANDOMIZED-TRIAL
dc.subjectORAL ALENDRONATE
dc.subjectDENSITY
dc.subjectRISK
dc.subjectMECHANISMS
dc.subjectSYMPTOMS
dc.titleGastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis
dc.typearticle
dspace.entity.typePublication
local.avesis.ideabd58ff-f622-45b8-b8e1-cfd12a551965
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages7
oaire.citation.endPage967
oaire.citation.issue6
oaire.citation.startPage961
oaire.citation.titleYONSEI MEDICAL JOURNAL
oaire.citation.volume44
relation.isAuthorOfPublicationa0d3ad8e-a3dd-44d0-98b7-d3eb31f6a0c9
relation.isAuthorOfPublication.latestForDiscoverya0d3ad8e-a3dd-44d0-98b7-d3eb31f6a0c9

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Aki et al. - 2003 - Gastrointestinal Side Effect Profile Due to the Us.pdf
Size:
764.61 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs